ABEC’s Custom Individual Execution Generation (CS®R) for the production of approximately one billion doses of the Novavax COVID-19 vaccine
ABEC, one of the world’s leading suppliers of embedded solutions and facilities for the manufacture of biopharmaceutical products, today announced its assistance to the Serum Institute of India Pvt. Ltd. (SIIPL) in Pune, India, by delivering six CSR 4,000 L bioreactors for the manufacture of the Candidate Vaccine Novavax COVID-19, NVX-CoV2373. Serum Institute, the world’s largest manufacturer of vaccines by dose quantity, will use the single-use ABEC vaccine. technologies to promote the global source of NVX-CoV2373 India and low- and middle-income countries.
The new Serum Institute facility will be the world’s largest single-use bioreactor vaccine production line. ABEC’s single-use 4,000 L CSR bioreactors are the largest in the industry thanks to a two-way thing, consistent with allowing the Serum Institute to double productivity according to the ground area unit and to achieve the lowest imaginable load consistent with the dose. Taking advantage of its global presence, ABEC manufactures single-use bioreactors and disposable boxes (DCs) at its facilities in the United States and Ireland to meet the Serum Institute’s accelerated program. ABEC’s ISO-7 multi-site global cleanrooms ensure a physically powerful source chain with the industry’s shortest DC deadlines, in line with the Serum Institute’s commitment to start production in early 2021.
“We are proud to be part of the Serum Institute’s pressure paints to deliver the Novavax COVID-19 vaccine,” said Scott Pickering, president and CEO of ABEC. “This critical task exemplifies and is made imaginable through all the fundamental values on which ABEC is based: integrity, credibility, wise leadership, flexibility and long-term commitment. “
About ABEC
Since 1974, ABEC has been a world leader in the offering of built-in procedures and production facilities in the biopharmaceutical industry. Most of the world’s pharmaceutical and biotech corporations are ABEC customers; with many of the current treatments performed through procedures and devices designed, manufactured, installed and maintained through ABEC. ABEC’s exclusive price is based on long experience, comprehensive internal capabilities, a personalized and flexible technique and long-term credibility. improving existing facilities, ABEC turnkey responses and support facilities reduce overall prices and time to market while delivering maximum productivity. For more information about ABEC, visit abec. com, email info@abec. com and stay with us on LinkedIn.
See the edition in businesswire. com: https://www. businesswire. com/news/home/20200930005056/fr/
Contacts
Media: ABECSusan Cooper Curcio 1 (610) 861 4666scurcio@abec. com